Biomarkers in Sarcoidosis: Beginning of a New Era?

Sophie C van der Mark; Vikaash W S Bajnath; Marcel Veltkamp

doi:10.1016/j.ccm.2023.09.002

Biomarkers in Sarcoidosis: Beginning of a New Era?

Clin Chest Med. 2024 Mar;45(1):33-43. doi: 10.1016/j.ccm.2023.09.002. Epub 2023 Oct 11.

Authors

Sophie C van der Mark¹, Vikaash W S Bajnath², Marcel Veltkamp³

Affiliations

¹ Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands; Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.
² Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
³ Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands; Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands. Electronic address: m.veltkamp@antoniusziekenhuis.nl.

PMID: 38245369
DOI: 10.1016/j.ccm.2023.09.002

Abstract

At present, no biomarker exists which is truly specific for sarcoidosis and the ones available have modest sensitivity and specificity. The clinical context should dictate the choice of biomarker(s) used to address different clinical questions such as diagnosis, monitoring disease activity or monitoring response to treatment. In the future, in addition to known serum biomarkers, it seems fruitful to further explore a possible role of imaging, exhaled air and even biopsy-related biomarkers in sarcoidosis to guide clinical management.

Keywords: FDG-PET; Future biomarkers; Sarcoidosis; Serum biomarkers.

Publication types

Review

MeSH terms

Biomarkers
Fluorodeoxyglucose F18*
Humans
Positron-Emission Tomography / methods
Sarcoidosis* / diagnosis
Sarcoidosis* / therapy
Sensitivity and Specificity

Substances

Fluorodeoxyglucose F18
Biomarkers